These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 36725065)
1. The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis. Hasegawa E; Ito S; Kurosawa Y; Kobayashi D; Otani H; Abe A; Nakazono K; Murasawa A; Narita I; Ishikawa H Intern Med; 2023; 62(3):373-379. PubMed ID: 36725065 [TBL] [Abstract][Full Text] [Related]
2. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis. Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Torii M; Hashimoto M; Hanai A; Fujii T; Furu M; Ito H; Uozumi R; Hamaguchi M; Terao C; Yamamoto W; Uda M; Nin K; Morita S; Arai H; Mimori T Mod Rheumatol; 2019 Jul; 29(4):589-595. PubMed ID: 30092163 [No Abstract] [Full Text] [Related]
4. Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study. Tada M; Matsumoto Y; Koike T; Mamoto K; Nakamura T; Anno S; Iida T; Goto H; Hidaka N Int J Rheum Dis; 2024 Oct; 27(10):e15371. PubMed ID: 39381837 [TBL] [Abstract][Full Text] [Related]
5. Association between Bone Mineral Density of Femoral Neck and Geriatric Nutritional Risk Index in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs. Tokumoto H; Tominaga H; Arishima Y; Jokoji G; Akimoto M; Ohtsubo H; Taketomi E; Sunahara N; Nagano S; Ishidou Y; Komiya S; Setoguchi T Nutrients; 2018 Feb; 10(2):. PubMed ID: 29463015 [TBL] [Abstract][Full Text] [Related]
6. Factors associated with sarcopenia in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study. Nakayama M; Furuya T; Inoue E; Tanaka E; Ikari K; Yamanaka H; Harigai M Clin Rheumatol; 2024 Jan; 43(1):521-526. PubMed ID: 37731082 [TBL] [Abstract][Full Text] [Related]
7. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study. Kim SK; Choe JY; Park SH; Lee H Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795 [TBL] [Abstract][Full Text] [Related]
8. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647 [TBL] [Abstract][Full Text] [Related]
9. Predictive factors for radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs): Results of 3 to 4 years of follow-up. Nakajima A; Terayama K; Sonobe M; Aoki Y; Takahashi H; Akatsu Y; Taniguchi S; Yamada M; Kubota A; Nakagawa K Mod Rheumatol; 2019 Nov; 29(6):903-909. PubMed ID: 30285585 [No Abstract] [Full Text] [Related]
10. Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study. Maeda Y; Hirano T; Ebina K; Hara R; Hashimoto M; Yamamoto W; Murakami K; Kotani T; Hata K; Son Y; Amuro H; Onishi A; Jinno S; Katayama M; Kumanogoh A Rheumatol Int; 2021 Jul; 41(7):1233-1241. PubMed ID: 33903963 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study. Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078 [TBL] [Abstract][Full Text] [Related]
13. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046 [TBL] [Abstract][Full Text] [Related]
14. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib. Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316 [TBL] [Abstract][Full Text] [Related]
15. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Ishikawa Y; Hashimoto M; Ito H; Tanaka M; Yukawa N; Fujii T; Yamamoto W; Mimori T; Terao C Semin Arthritis Rheum; 2019 Oct; 49(2):204-210. PubMed ID: 30803720 [TBL] [Abstract][Full Text] [Related]
16. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438 [TBL] [Abstract][Full Text] [Related]
17. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813 [TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. Novella-Navarro M; Plasencia C; Tornero C; Navarro-Compán V; Cabrera-Alarcón JL; Peiteado-López D; Nuño L; Monjo-Henry I; Franco-Gómez K; Villalba A; Balsa A Arthritis Res Ther; 2020 Dec; 22(1):284. PubMed ID: 33298140 [TBL] [Abstract][Full Text] [Related]
19. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort. Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367 [TBL] [Abstract][Full Text] [Related]
20. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL; Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]